BR112021008582A8 - Regime de dosagem de anticorpo anti-tigit para tratamento de câncer - Google Patents

Regime de dosagem de anticorpo anti-tigit para tratamento de câncer

Info

Publication number
BR112021008582A8
BR112021008582A8 BR112021008582A BR112021008582A BR112021008582A8 BR 112021008582 A8 BR112021008582 A8 BR 112021008582A8 BR 112021008582 A BR112021008582 A BR 112021008582A BR 112021008582 A BR112021008582 A BR 112021008582A BR 112021008582 A8 BR112021008582 A8 BR 112021008582A8
Authority
BR
Brazil
Prior art keywords
tigit antibody
cancer treatment
dosage regime
antibody dosage
cancer
Prior art date
Application number
BR112021008582A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021008582A2 (pt
Inventor
Cai Mingmei
K Chartash Elliot
Anne Healy Jane
Lala Mallika
Ruosi Li Tommy
Mayawala Kapil
Andreia Predoiu Raluca
M G Williams Sybil
Zeng Zhen
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112021008582A2 publication Critical patent/BR112021008582A2/pt
Publication of BR112021008582A8 publication Critical patent/BR112021008582A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BR112021008582A 2018-11-05 2019-11-04 Regime de dosagem de anticorpo anti-tigit para tratamento de câncer BR112021008582A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Publications (2)

Publication Number Publication Date
BR112021008582A2 BR112021008582A2 (pt) 2021-08-10
BR112021008582A8 true BR112021008582A8 (pt) 2023-02-07

Family

ID=70611082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021008582A BR112021008582A8 (pt) 2018-11-05 2019-11-04 Regime de dosagem de anticorpo anti-tigit para tratamento de câncer

Country Status (10)

Country Link
US (1) US20210403557A1 (https=)
EP (1) EP3877418A4 (https=)
JP (2) JP2022512851A (https=)
KR (1) KR20210091209A (https=)
CN (1) CN113302204A (https=)
AU (1) AU2019375409A1 (https=)
BR (1) BR112021008582A8 (https=)
CA (1) CA3118964A1 (https=)
MX (1) MX2021005236A (https=)
WO (1) WO2020096915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN115916348A (zh) * 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
US20240262915A1 (en) * 2020-09-22 2024-08-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-tigit antibody and double antibody and their application
EP4384550A4 (en) * 2021-08-10 2025-06-18 Merck Sharp & Dohme LLC THERAPEUTIC COMBINATION WITH A TIGIT ANTAGONIST, A PD-1 ANTAGONIST AND LENVATINIB
KR20240047393A (ko) * 2021-08-10 2024-04-12 머크 샤프 앤드 돔 엘엘씨 Tigit 길항제, pd-1 길항제 및 화학요법제(들)를 포함하는 치료 조합물
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2015305754B2 (en) * 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
AU2017269675A1 (en) * 2016-05-26 2019-01-17 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for cancer treatment
SMT202300418T1 (it) * 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody

Also Published As

Publication number Publication date
CA3118964A1 (en) 2020-05-14
WO2020096915A1 (en) 2020-05-14
EP3877418A4 (en) 2022-08-17
JP2025004212A (ja) 2025-01-14
JP2022512851A (ja) 2022-02-07
US20210403557A1 (en) 2021-12-30
KR20210091209A (ko) 2021-07-21
EP3877418A1 (en) 2021-09-15
MX2021005236A (es) 2021-06-18
CN113302204A (zh) 2021-08-24
AU2019375409A1 (en) 2021-05-27
BR112021008582A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer
BR112021022831A2 (pt) Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1
BR112018068512A2 (pt) métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
PH12019500270A1 (en) Combination therapy for cancer
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
JOP20220163B1 (ar) مركب بيريدازينيل-ثيازول كربوكساميد
BR112019003989A2 (pt) métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
BR112022011998A2 (pt) Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
BR112018075371A2 (pt) usos terapêuticos de um inibidor de c-raf
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
MX384141B (es) Métodos para monitorear y terapias para usarse en tratar el cáncer.
MY195474A (en) Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1)
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
DOP2016000071A (es) Inhibidores de tirosina cinasa de bruton
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112018072953A2 (pt) polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
MY205639A (en) Fgfr/pd-1 combination therapy for the treatment of cancer
BR112016007479A2 (pt) regimes de dosagem de imunoconjugado de anti-folr1
BR112022012437A2 (pt) Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
BR112021006223A2 (pt) regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)